21279-79-8

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-chloropropyl)-4-(4-methoxyphenyl)piperazine is used as a pharmaceutical compound for its potential therapeutic applications in treating various medical conditions. Its pharmacological properties are being investigated to determine its efficacy and safety in clinical settings.
Used in Chemical Synthesis:
1-(3-chloropropyl)-4-(4-methoxyphenyl)piperazine is used as a precursor in the synthesis of other organic compounds. Its unique structural features make it a valuable building block for creating new molecules with specific properties and applications in various industries.
Used in Research and Development:
1-(3-chloropropyl)-4-(4-methoxyphenyl)piperazine is used as a research compound to study its pharmacological properties and potential applications in medicine. This includes understanding its interactions with biological systems and evaluating its effectiveness in treating specific conditions.

Upstream product

• 38212-30-5 4-(4-methoxyphenyl)piperazine 
• 109-70-6 1.3-chlorobromopropane 

Downstream Products

• 84344-57-0 1-(4-nitrophenoxy)-3-1-(N⁴-(4-methoxyphenyl)piperazinyl)>propane 
• 84344-59-2 4-{3-[4-(4-Methoxy-phenyl)-piperazin-1-yl]-propoxy}-benzaldehyde 
• 84344-65-0 4-{3-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-yl]-propoxy}-benzaldehyde 
• 84344-58-1 3-{3-[4-(4-Methoxy-phenyl)-piperazin-1-yl]-propoxy}-benzaldehyde 
• 482647-39-2 4-methoxy-7-{3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propoxy}-chromen-2-one 
• 482647-38-1 4-methoxy-6-{3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propoxy}-chromen-2-one 
• 482647-51-8 4-hydroxy-7-{3-[4-(p-methoxyphenyl)-1-piperazinyl]propyloxy}coumarin 
• 482647-50-7 4-hydroxy-6-{3-[4-(p-methoxyphenyl)-1-piperazinyl]propyloxy}coumarin 
• 1243651-30-0 3,4-dihydro-1-[3-(4-(4-methoxyphenyl)piperazin-1-yl)propyl]quinolin-2(1H)-one 

Relevant academic research and scientific papers

Structure-affinity relationship studies on benzotriazole derivatives binding to 5-HT receptor subtypes

A number of benzotriazole derivatives have been assayed in radioligand binding experiments involving the following recombinant human serotonin receptors: 5-HT(2A), 5-HT(1A), 5-HT(1Dβ) and 5-HT(2C). Several of the compounds tested show interesting selectivity profiles. In particular, the affinities of 3d, 4a and 4d for the 5-HT(2A) subtype (with pK(i) values of 7.4, 7.4 and 8.0, respectively) are between 100 and 1000 times higher than for the other investigated receptors. Compound 5l, characterized by a pK(i) value of 7.4 on the 5-HT(1A) receptor, binds with 100- to 1000-fold lower potencies on the other receptors. Our benzotriazole derivatives are generally weak ligands of the 5-HT(1Dβ) and 5-HT(2C) receptors. Structure-affinity relationship data suggest that not all the compounds exhibit the same binding mode at the 5-HT(2A) and 5-HT(1A) receptors.

Synthesis, 3D-QSAR, and structural modeling of benzolactam derivatives with binding affinity for the D2and D3 receptors

A series of 37 benzolactam derivatives were synthesized, and their respective affinities for the dopamine D2 and D3 receptors evaluated. The relationships between structures and binding affinities were investigated using both ligand-based (3D-QSAR) and receptor-based methods. The results revealed the importance of diverse structural features in explaining the differences in the observed affinities, such as the location of the benzolactam carbonyl oxygen, or the overall length of the compounds. The optimal values for such ligand properties are slightly different for the D2 and D 3 receptors, even though the binding sites present a very high degree of homology. We explain these differences by the presence of a hydrogen bond network in the D2 receptor which is absent in the D3 receptor and limits the dimensions of the binding pocket, causing residues in helix 7 to become less accessible. The implications of these results for the design of more potent and selective benzolactam derivatives are presented and discussed.

Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands

A series of new benzolactam derivatives was synthesized and the derivatives were evaluated for their affinities at the dopamine D1, D2, and D3 receptors. Some of these compounds showed high D2 and/or D3/su

Preparation of piperazine derivatives as 5-HT7 receptor antagonists

Twenty-four compounds of 4-methoxy-N-[3-(4-substituted phenyl-piperazine-1-yl)propyl] benzene sulfonamides and N-[3-(4-substituted phenyl-piperazine-1-yl)propyl] naphthyl sulfonamides were prepared and evaluated as 5-HT7 receptor antagonists. Most of the compounds showed the IC50 values of 12-580 nM. Four methyl branched analogues were also obtained, but the activity for methyl branched analogues was almost same as its straight chain congeners. Among the synthesized compounds, 3c showed a good activity on 5-HT7 receptors and a good selectivity on 5-HT1a, 5-HT2a, 5-HT2c, and 5-HT6 receptors.

Microwave-assisted solvent-free synthesis of 3-[(4-substituted piperazin-1-yl)alkyl] imidazo[2,1-b][1,3]benzothiazol-2(3H)-ones as serotonin3 (5-HT3) receptor antagonists

A series of novel 3-[(4-substituted piperazin-1-yl)alkyl]imidazo[2,1-b][1, 3]benzothiazol-2(3H)-ones were prepared by microwave irradiation using alumina as solid support and also by a conventional method. The compounds were characterized by spectral data and the purity was ascertained by microanalysis. The synthesized compounds were evaluated for 5-hydroxytryptamine3 antagonisms in a longitudinal muscle-myenteric plexus preparation from guinea pig ileum against the 5-hydroxytryptamine3 agonist, 2-methyl-5-hydroxytryptamine. Among the test compounds, 3-[2-(4-methylpiperazin- 1-yl)ethyl]imidazo[2,1-6][1,3]benzothiazol-2(3H)-one (3b) showed most favorable 5-hydroxytryptamine3 antagonism (pA2 6.7) in the isolated guinea pig ileum.

Synthesis and structure-activity relationships of new arylpiperazines: Para substitution with electron-withdrawing groups decrease binding to 5-HT1A and D2A receptors

Compounds in which N-phenylpiperazines were linked by a propyloxy chain to position 6 or 7 of a coumarin ring were designed and synthesised, and their affinities for 5-HT1A and D2A receptors were determined by radioligand binding assays. The influence of para substitution in the phenyl ring, substitution at position 4 of the coumarin system, and the coumarin position at which the piperazinylalkyl chain is linked was explored. Electron-withdrawing phenyl ring substituents para to the piperazine strongly reduced activity at both receptors. Binding at 5HT1A was influenced by the bulk of substituents at position 4 of the coumarin system, and binding at D2A by their electronic properties. Neither binding affinity was significantly affected by whether the piperazinylalkyl chain was inserted at position 6 or 7 of the coumarin system.

Synthesis of new 1,2,3-benzotriazin-4-one-arylpiperazine derivatives as 5-HT(1A) serotonin receptor ligands

A series of novel 1,2,3-benzotriazin-4-one derivatives was prepared and evaluated as ligands for 5-HT receptors. Radioligand binding assays proved that the majority of the novel compounds behaved as good to excellent ligands at the 5-HT(1A) receptor, some of which were selective with respect 5-HT(2A) and 5-HT(2C) receptors. Six analogues (1a, 2a, 2b, 2c, 2e and 2i) were selected and further evaluated for their binding affinities on D1, D2 dopaminergic and α1-, α2-adrenergic receptors. A o-OCH3 derivative (2e) bound at 5-HT(1A) sites with subnanomolar affinity (IC50=0.059 nM) and shows high selectivity over all considered receptors and may offer a new lead for the development of therapeutically efficacious agents. Copyright (C) 2000 Elsevier Science Ltd.

Synthesis and Biological Activities of 3-Substituted 1-Aryloxyaminopropanes

A number of 3-substituted 1-aryloxyaminopropanes (9-43) have been prepared by the reaction of appropriate hydroxyaryl compound with 1-chloro-3-1-(N4-aryl-piperazinyl/piperidinyl)>propanes (1-8).The 1-(6/7-quinolyloxy)-3-substituted